arrow
K

Khaled M. Musallam

burjeel medical city
H指数:53
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Thalassaemia

Publisher Correction: 地中海贫血

2026-10-300
PRE
Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration

为地中海贫血护理的未来做准备:利用可扩展疗法、人工智能和全球合作

2026-10-060
PRE
Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3trial

米塔匹泛在依赖输血的α-地中海贫血或β-地中海贫血成人中的有效性和安全性(ENERGIZE-T):一项双盲、随机、多中心、安慰剂对照、III期临床试验

2026-09-121
PRE
Thalassaemia

地中海贫血

2026-07-090
PRE
Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990–2023: a population-based modelling study

WHO血红蛋白升高调整指南的变更对全球、区域和国家贫血负担的影响(1990–2023年):一项基于人群的建模研究

2026-04-020
PRE
Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources

新型疗法时代输血依赖性β-地中海贫血的管理:一种基于优先级的矩阵,适用于资源有限的环境

2025-12-310
PRE
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial

通过Luspatercept治疗非输血依赖性β-地中海贫血患者实现血红蛋白水平的临床显著变化:一项BEYOND试验2期研究的事后分析

2025-10-260
PRE
Quantifying Morbidity Risk Attributed to Red-Cell Transfusion Volume in Optimally Transfused Patients With β-Thalassemia

量化最优输血患者中红细胞输注量所致的发病风险

2025-10-030
OAAI
Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study

luspaterecpt 在非输血依赖性β-地中海贫血中的有效性和安全性:BEYOND研究的长期能力结果

2025-09-010
OAAI
Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study

β-地中海贫血中贫血和铁控制对预后的影响:纵向de-LIGHT研究的数据

2025-07-310
PRE
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial

米塔吡范(mitapivat)用于非输血依赖性α-地中海贫血或β-地中海贫血成人患者的治疗(ENERGIZE):一项III期、国际、随机、双盲、安慰剂对照试验

2025-06-190
PRE